Xylo Technologies Ltd. (XYLO) - Net Assets

Latest as of December 2024: $17.59 Million USD

Based on the latest financial reports, Xylo Technologies Ltd. (XYLO) has net assets worth $17.59 Million USD as of December 2024. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($37.55 Million) and total liabilities ($19.96 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Xylo Technologies Ltd. liquidity resilience to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets $17.59 Million
% of Total Assets 46.84%
Annual Growth Rate 25.14%
5-Year Change -32.85%
10-Year Change N/A
Growth Volatility 82.86

Xylo Technologies Ltd. - Net Assets Trend (2016–2024)

This chart illustrates how Xylo Technologies Ltd.'s net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Xylo Technologies Ltd. for the complete picture of this company's asset base.

Annual Net Assets for Xylo Technologies Ltd. (2016–2024)

The table below shows the annual net assets of Xylo Technologies Ltd. from 2016 to 2024. For live valuation and market cap data, see XYLO market cap.

Year Net Assets Change
2024-12-31 $17.59 Million -45.77%
2023-12-31 $32.44 Million -40.69%
2022-12-31 $54.69 Million +6.33%
2021-12-31 $51.43 Million +96.35%
2020-12-31 $26.19 Million +222.15%
2019-12-31 $8.13 Million +0.64%
2018-12-31 $8.08 Million +46.60%
2017-12-31 $5.51 Million +88.46%
2016-12-31 $2.92 Million --

Equity Component Analysis

This analysis shows how different components contribute to Xylo Technologies Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 5435089100.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Other Comprehensive Income $11.30 Million 62.86%
Other Components $114.32 Million 635.66%
Total Equity $17.98 Million 100.00%

Xylo Technologies Ltd. Competitors by Market Cap

The table below lists competitors of Xylo Technologies Ltd. ranked by their market capitalization.

Company Market Cap
FRESH FACTORY B.C.
F:Q4Z
$6.50 Million
Fobi AI Inc
V:FOBI
$6.50 Million
Intelligent Bio Solutions Inc.
NASDAQ:INBS
$6.50 Million
E79 Gold Mines Ltd
AU:E79
$6.50 Million
The Calmer Co International Ltd
AU:CCO
$6.49 Million
NGS Group AB (publ)
ST:NGS
$6.49 Million
EXPLOITS DISCOVERY CORP.
F:634
$6.49 Million
Tourn International AB
ST:TOURN
$6.49 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Xylo Technologies Ltd.'s equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 23,576,000 to 17,984,000, a change of -5,592,000 (-23.7%).
  • Net loss of 6,027,000 reduced equity.
  • New share issuances of 1,588,000 increased equity.
  • Other comprehensive income decreased equity by 999,000.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income $-6.03 Million -33.51%
Share Issuances $1.59 Million +8.83%
Other Comprehensive Income $-999.00K -5.55%
Other Changes $-154.00K -0.86%
Total Change $- -23.72%

Book Value vs Market Value Analysis

This analysis compares Xylo Technologies Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.20x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2016-12-31 $34.01 $5.07 x
2017-12-31 $17.00 $5.07 x
2018-12-31 $7.70 $5.07 x
2019-12-31 $3.43 $5.07 x
2020-12-31 $6.88 $5.07 x
2021-12-31 $4.27 $5.07 x
2022-12-31 $64.21 $5.07 x
2023-12-31 $37.29 $5.07 x
2024-12-31 $24.95 $5.07 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Xylo Technologies Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -33.51%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -20.19%
  • • Asset Turnover: 0.80x
  • • Equity Multiplier: 2.09x
  • Recent ROE (-33.51%) is above the historical average (-86.53%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2016 -307.94% -1640.62% 0.12x 1.61x $-9.30 Million
2017 -46.18% -544.97% 0.06x 1.31x $-3.10 Million
2018 -81.67% -1513.30% 0.04x 1.39x $-7.41 Million
2019 -211.39% -5193.41% 0.02x 1.99x $-14.85 Million
2020 -18.84% -814.50% 0.02x 1.41x $-6.62 Million
2021 13.81% 67.15% 0.17x 1.21x $1.88 Million
2022 -25.08% -10.68% 0.94x 2.49x $-13.73 Million
2023 -67.97% -17.47% 1.44x 2.71x $-18.38 Million
2024 -33.51% -20.19% 0.80x 2.09x $-7.83 Million

Industry Comparison

This section compares Xylo Technologies Ltd.'s net assets metrics with peer companies in the Medical Devices industry.

Industry Context

  • Industry: Medical Devices
  • Average net assets among peers: $2,432,799,891
  • Average return on equity (ROE) among peers: -74.29%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Xylo Technologies Ltd. (XYLO) $17.59 Million -307.94% 1.13x $6.49 Million
Abbott Laboratories (ABT) $24.16 Billion 9.46% 0.81x $155.56 Billion
Adagio Medical Holdings, Inc Common Stock (ADGM) $-13.54K 0.00% 0.00x $21.60 Million
Aethlon Medical Inc (AEMD) $9.29 Million -84.45% 0.15x $2.79 Million
Acutus Medical Inc (AFIB) $105.73 Million -116.68% 0.61x $903.35K
Adapthealth Corp (AHCO) $15.14 Million -140.98% 14.05x $1.39 Billion
20/20 Biolabs, Inc. Common Stock (AIDX) $2.15 Million -112.84% 0.45x $16.04 Million
Allurion Technologies, Inc. (ALUR) $-70.49 Million 0.00% 0.00x $8.60 Million
Autonomix Medical, Inc. Common Stock (AMIX) $644.00K -309.01% 0.34x $4.22 Million
Artivion Inc (AORT) $89.39 Million 8.74% 0.25x $1.73 Billion
Apyx Medical Inc (APYX) $21.15 Million 2.82% 0.30x $125.55 Million

About Xylo Technologies Ltd.

NASDAQ:XYLO USA Medical Devices
Market Cap
$6.49 Million
Market Cap Rank
#27850 Global
#5503 in USA
Share Price
$5.07
Change (1 day)
+0.00%
52-Week Range
$4.78 - $5.35
All Time High
$5701.20
About

Xylo Technologies Ltd, a technology-based company, provides medical-related devices and products in the United States, Europe, Great Britain, Israel, Canada, Asia, and internationally. It operates through Corporate, Online Advertising & Internet Traffic Routing, Online Event Management, and Real-estate and Electronics segments. The company offers Medigus Ultrasonic Surgical Endostapler, an endosc… Read more